Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
2,060
Views
0
CrossRef citations to date
0
Altmetric
Genetic Disease

Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B

Tom Burkea HCD Economics, Daresbury, Cheshire, UK;b Faculty of Health and Social Care, University of Chester, Chester, Cheshire, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6768-1670
ORCID Icon,
Anum Shaikha HCD Economics, Daresbury, Cheshire, UK
,
Talaha M. Alic uniQure Inc, Lexington, MA, USA
,
Nanxin Lic uniQure Inc, Lexington, MA, USA
,
Randall Curtisd Factor VIII Computing, Berkeley, CA, USAORCID Iconhttps://orcid.org/0000-0002-6859-6432
ORCID Icon,
Daniel-Anibal Garcia Diegoe Federación Española de Hemofilia (FEDHEMO), Madrid, Spain
,
Michael Rechtf Oregon Health & Science University, Portland, OR, USA;g American Thrombosis and Hemostasis Network, Rochester, NY, USA
,
Thomas Sannieh Association Française des Hémophiles, Paris, Île-de-France, France
,
Mark Skinneri Institute for Policy Advancement, Ltd, Washington, DC, USA;j McMaster University, Hamilton, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-0934-0680
ORCID Icon &
Jamie O’Haraa HCD Economics, Daresbury, Cheshire, UK;b Faculty of Health and Social Care, University of Chester, Chester, Cheshire, UKORCID Iconhttps://orcid.org/0000-0001-8262-034X
ORCID Icon show all
Pages 386-392 | Received 10 Jan 2022, Accepted 02 Mar 2022, Published online: 15 Mar 2022

References

  • Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939.
  • Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus. 2013;11(2):178–182.
  • Chen CX, Baker JR, Nichol MB. Economic burden of illness among person with hemophilia B from HUGS Vb: examining the association of severity and treatment regimens with costs and annual bleed rates. Value Health. 2017;20(8):1074–1082.
  • Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189–199.
  • Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677–1686.
  • Schrijvers LH, Beijlevelt‐van der Zande M, Peters M, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016;174(3):454–460.
  • O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.
  • Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the pain, functional impairment, and quality of life (P-FiQ) study. Haemophilia. 2017;23(4):556–565.
  • Witkop ML, Lambing A, Nichols CD, et al. Interrelationship between depression, anxiety, pain, and treatment adherence in hemophilia: results from a US cross-sectional survey. PPA. 2019;13:1577–1587.
  • O'Hara J, Walsh S, Camp C, et al. The relationship between target joints and direct resource use in severe haemophilia. Health Econ Rev. 2018;8(1):1.
  • Spadarella G, Minno AD, Milan G, et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev. 2020;39:100618.
  • Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold? Blood Rev. 2018;32(1):52–60.
  • den Uijl IEM, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44.
  • Nathwani A. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019;2019(1):1–8.
  • Burke T, Shaikh A, Ali TM, et al. Bleeding data across baseline FIX expression level in people with hemophilia B: an analysis using the ‘factor expression study. Blood. 2021;138(Supplement 1):592–592.
  • Burke T, Asghar S, O'Hara J, et al. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US + population surveys. Orphanet J Rare Dis. 2021;16(1):143.
  • O'Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.
  • Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
  • O'Hara J, Martin AP, Nugent D, et al. Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia. 2021;27(2):245–252.
  • Harrell FE, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80(15):1198–1202.
  • Pierce GF, Ragni MV, van den Berg HM, et al. Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia. 2017;23(5):643–644.
  • Orio A, Skinner MW, Clearfield E, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018;24(4):e167–e172.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.